Gilead Sciences crushed revenue expectations with a $7.8 billion quarter—up 10% year-over-year—but missed slightly on full-year revenue forecasts. Adjusted EPS, which was a loss, beat analyst estimates, and they boosted their earnings outlook significantly. While HIV growth slowed, overall performance remained strong across cancer and hepatitis treatments. Free cash flow margins jumped, signaling improved financial health. Analysts predict flat revenue next year, and the stock held steady—suggesting investors are weighing both the wins and the cautious outlook.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
